LBT signs agreement with bioMerieux for MicroStreak

Published: 27-Aug-2015
Analysis

Both companies will be free to pursue their development in laboratory automation independently


Australian medical technology company LBT Innovations has signed a licence agreement with the French in vitro diagnostics company bioMérieux for LBT’s foundational culture plate-streaking technology, MicroStreak.

The agreement terminates the initial exclusive licence signed in 2007 and converts it to a non-exclusive licence. Both companies will be free to pursue their development in laboratory automation independently.

Under the new license bioMérieux will retain the sole rights to service and support the installed base of PREVI Isola systems, including supply of the patented disposable applicators used in the streaking process, and will discontinue sales of new systems by 30 July 2016. bioMerieux will focus its resources on the strategic alliance the company entered on 9 January 2015 with the Italian company Copan.

Under the new arrangements, LBT Innovations will receive a one-time, full and final upfront payment of US$5.5m (AU$7.7m) payable within 14 days of LBT's invoice, and will receive non-exclusive technology rights to improvements developed by bioMérieux as solely related to the MicroStreak technology. LBT will recover global rights to pursue its own development, manufacturing and commercialisation of a MicroStreak product.

'We fully understand bioMérieux’s decision regarding PREVI Isola and we have taken this as an opportunity to reposition MicroStreak and to explore other opportunities that exist for the technology,' said LBT’s Chief Executive Officer, Lusia Guthrie.

'We have been extremely fortunate to have had a partner of bioMérieux’s calibre and reputation, which has helped to establish MicroStreak as a valuable and commercially successful technology at the leading edge of microbiology automation.'

  • Companies:
  • bioMerieux
See more

You may also like

Regulatory

UPDATE: US Pharmacopeia makes comments public on endotoxin testing overhaul

Read more
The USP has published the comments the organisation received in response to the addition of non-animal derived endotoxin testing methods, as well as an FAQ page on the issue

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Integrity testing of HEPA filters: A practical approach Filtering the air in aseptic process areas is critical to maintaining the cleanliness of the production environment. Jesus Casas provides tips to ensure HEPA filters are fit for purpose once installed in your facility
  2. Microbiological monitoring: Adapting to new rapid methods regulatory demands Dr Wan Li Low from Cherwell takes a look at the shift towards Rapid Microbiology Methods (RMM) and their validation
  3. Germfree launches Smarthood for sterile compounding The cleanroom containment expert has launched Smarthood to integrate IV production workflow software, hardware, and peripherals directly into the hood
  4. A guide to choosing the best particle sample point location Particle counting in pharmaceutical applications can be clearly segregated into one of three categories: certification, qualification and monitoring. Each category requires a different approach as explained by PMS' Mark Hallworth
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Phoenix Controls launches dynamic airflow management solution for critical environments The platform uses specialised venturi valves and sensors to create automated airflow in response to environmental fluctuations in cleanrooms and other controlled environments

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

UPDATE: US Pharmacopeia makes comments public on endotoxin testing overhaul

The USP has published the comments the organisation received in response to the addition of non-animal derived endotoxin testing methods, as well as an FAQ page on the issue
Analysis

bioMérieux and JMI partner to fight antimicrobial resistance

The two firms have announced a six year partnership to undertake collaborative projects evaluating the performance and increasing potential of rapid and innovative microbiology diagnostics as important tools in the battle against AMR
Cleaning

bioMérieux launches assay for simultaneous Salmonella and Listeria detection

France-based bioMérieux has introduced GENE-UP ENVIROPRO that simultaneously detects both Salmonella and Listeria through a single enriched sample with PCR confirmation
Cleaning

Astrazeneca chooses LBT to develop automated microbial QC product

LBT Innovations has been engaged by AstraZeneca to undertake a full product development project for the company’s new APAS Pharma analysis module (artificial intelligence software) to be used on the APAS Independence instrument
Finance

bioMerieux acquires molecular testing company

The acquisition of the molecular testing platform, Veriflow, will compliment bioMérieux’s Gene-up system
Analysis

US FDA approves LBT’S Automated Plate Assessment System

FDA clears APAS imaging and software technology as a Class II medical device
Analysis

bioMérieux launches automated diagnostic solution for microbial detection

EviSight Compact provides reliable results for increased product safety and reduces costs for pharmaceutical companies
Subscribe now